New combo shows promise for Tough-to-Treat colorectal cancer

This phase 3 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and bevacizumab helps people with a specific type of advanced colorectal cancer (RAS-mutant, MSS) live longer without their cancer growing. About 446 adults who have not had prior treatment will be randomly assigned to receive either the standard therapy or the standard therapy plus sintilimab. The study aims to see if the combination improves outcomes like tumor shrinkage and survival.